 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || RG7598 / Seagen, Roche
P1 data, Journal: Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. (Pubmed Central) - Jan 1, 2020
FcRH5 was confirmed to be expressed and occupied by antibody post-treatment and thus remains a valid myeloma target. Nevertheless, this MMAE-based antibody-drug-conjugate targeting FcRH5 was unsuccessful for myeloma.
- RG7598 / Roche
Trial primary completion date: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 10, 2014
P1, N=39, Completed, Sponsor: Genentech
Nevertheless, this MMAE-based antibody-drug-conjugate targeting FcRH5 was unsuccessful for myeloma. Trial primary completion date: Apr 2015 --> Apr 2014
- | RG7598 / Roche
Trial completion: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 10, 2014
P1, N=39, Completed, Sponsor: Genentech
Trial primary completion date: Apr 2015 --> Apr 2014 Recruiting --> Completed
- || RG7598 / Roche
Trial completion, Enrollment change, Trial primary completion date: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 6, 2014
P1, N=76, Recruiting, Sponsor: Genentech
Recruiting --> Completed N=45 --> 76 | Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2014
- ||| RG7598 / Roche
Enrollment open: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 18, 2011
P1, N=76, Recruiting, Sponsor: Genentech
N=45 --> 76 | Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Apr 2014 Not yet recruiting --> Recruiting
- ||| RG7598 / Roche
New P1 trial: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 11, 2011
P1, N=76, Recruiting, Sponsor: Genentech